WHO WE ARE

At ViiV Healthcare we do things differently. From our unique origins to our innovative medicines, we push the boundaries of what people think is possible in HIV treatment and care. 

If you should know one thing about us, know this: we will not rest until we leave no person living with HIV (PLHIV) behind. Until the 37 million PLHIV is down to zero, we will continue searching for new ways to limit the impact of HIV.[1]

Born out of a partnership between GSK and Pfizer in 2009, with Shionogi joining in 2012, at ViiV Healthcare we are determined to help end the HIV epidemic. Our one focused goal unites our 1100 employees located across over 20 countries, with their expertise in research, manufacturing, policy and more, all guided by our mission to be here until HIV isn’t.

Our current portfolio of 14 HIV treatments is our first step in fighting back against the disease. This is only the beginning as our research centre in Branford, Connecticut, the world’s only HIV-dedicated facility, is utterly focused on finding new innovative medicines to help improve the lives of PLHIV.

Also searching to find major breakthroughs against HIV is our industry-defining partnership with the HIV Cure Centre at the University of North Carolina. Part of a unique public-private collaboration ‘Qura Therapeutics’, we have been combining resources and expertise to accelerate novel breakthroughs and maximise the chance of finding a HIV cure.

Alongside our novel approach to R&D, improving access to medicines is just as impotant in delivering results for our patients. At ViiV Healthcare we are dedicated to widening access to ensure those who need our medicines can receive them. Collaborations with organisations such as IAS, CHAI and MPP enable our medicines to make the greatest possible impact in countries around the world. As an example, our voluntary licence agreements allow generic manufacturers to develop paediatric formulations of our medicines where 99% of children living with HIV live. We are committed to working ever closer with our partners through continued access initiatives.

To accelerate the eradication of HIV once and for all, we put significant focus on community initiatives to strengthen local healthcare services for PLHIV. Through our Positive Action programmes which back over 300 projects worldwide, our work with local communities aim to deliver long-lasting impacts on groups such as women and children. We seek to enhance local expertise and resources that build towards global goals including the WHO 90-90-90 targets, as well as our own dedicated mission of leaving no person living with HIV behind.[2]

[1] Global Health Observatory (GHO) data – HIV/AIDs. Available from: https://www.who.int/gho/hiv/en/. Last accessed: February 2019

[2] UNAIDS 90-90-90: Treatment for all. Available at: http://www.unaids.org/en/resources/909090. Last accessed: March 2019